Get to know our clinical trials
Trial of BMS-986278 in participants with progressive pulmonary fibrosis.
THE PURPOSE OF THIS STUDY IS TO LEARN MORE ABOUT A STUDY TREATMENT CALLED BMS 986278. THE STUDY TREATMENT WILL BE TESTED AT DOSES OF 120 MG OR 60 MG ADMINISTERED BY MOUTH TWICE DAILY) COMPARED TO PLACEBO, AN INACTIVE SUBSTANCE CONTAINING NO DRUG. THIS STUDY IS BEING CONDUCTED TO TEST THE EFFECT OF BMS 986278 IN IMPROVING YOUR PROGRESSIVE PULMONARY FIBROSIS (PPF), AND TO SEE HOW WELL YOUR BODY TOLERATES BMS 986278.
Technical Summary
- PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF BMS-986278 IN PARTICIPANTS WITH PROGRESSIVE PULMONARY FIBROSIS.
- Code EudraCT: 2023-503699-25
- Protocol number: IM027-1015
- Promoter: Bristol Myers Squibb
- Link to Clinical Trials
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.